Report Library
All ReportsBiomedtracker Entresto Pulse
May 11, 2016
Uptake of Entresto (NVS) in the US has been slow following approval in July 2015. Part of that is due to the time it has taken to secure
insurance coverage, but physicians have complained about other insurance barriers, as well, and there are also clinical factors that could play
a role. This 6-question survey of 23 cardiologists asks about the most important clinical and reimbursement barriers for the drug. It
also projects how changes in guidelines, prior-authorization, and copays could impact usage.
If you are a KOL Insight Subscriber, please access this report here, in our KOL Insight portal (Subscribers only).
If you are a KOL Insight Subscriber, please access this report here, in our KOL Insight portal (Subscribers only).
Indications Covered: | Chronic Heart Failure - Reduced Ejection Fraction (Chronic HFrEF) |
Additional Resources: